Linköping-based biotech startup Celluminova has raised SEK 20 million (~€1.85M / $2.15M) in June 2026 to develop new tools for stem cell research, including applications in cancer stem cell studies.
The round includes participation from new investor East Sweden Capital and existing backer Almi Invest.
What Celluminova does
Celluminova develops advanced research tools for stem cell biology, with a particular focus on:
- cancer stem cell research
- stem cell behavior analysis
- translational biomedical research applications
The company aims to improve how researchers study stem cell dynamics, which is a critical area for understanding cancer development, treatment resistance, and regenerative medicine.
Funding details
- Round: Other / growth financing
- Amount: SEK 20M
- Date: June 2026
- Sector: BioTech
- HQ: Linköping, Sweden
- Previous name: —
Market context
Stem cell research remains a foundational area of biotechnology, especially in oncology and regenerative medicine. A key challenge in the field is improving experimental tools that can reliably model and analyze rare or complex cell populations such as cancer stem cells.
Celluminova is positioned in the research infrastructure layer of biotech, providing enabling technologies rather than end therapeutics.
Company link
Official website: Celluminova
Bottom line
With fresh capital from regional investors and continued support from Almi Invest, Celluminova is strengthening its position in the biotech tools space, targeting one of the most complex research domains in modern life sciences: stem cell and cancer stem cell analysis.
